Strategies for the development of stimuli-responsive small molecule prodrugs for cancer treatment
Approved anticancer drugs typically face challenges due to their narrow therapeutic window, primarily because of high systemic toxicity and limited selectivity for tumors. Prodrugs are initially inactive drug molecules designed to undergo specific chemical modifications. These modifications render t...
Saved in:
Main Authors: | Yuxuan Tu (Author), Jianbao Gong (Author), Jing Mou (Author), Hongfei Jiang (Author), Haibo Zhao (Author), Jiake Gao (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Theranostic Small-Molecule Prodrug Conjugate for Neuroendocrine Prostate Cancer
by: Paulina Gonzalez, et al.
Published: (2023) -
Smart stimuli-responsive carrier-free nanoassembly of SN38 prodrug as efficient chemotherapeutic nanomedicine
by: Guanting Li, et al.
Published: (2023) -
Preparation of Glutathione-Responsive Paclitaxel Prodrug Based on Endogenous Molecule of L-Glutathione Oxidized for Cancer Therapy
by: Xiao Duan, et al.
Published: (2024) -
pH-triggered dynamic erosive small molecule chlorambucil nano-prodrugs mediate robust oral chemotherapy
by: Xin Liu, et al.
Published: (2023) -
YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer
by: Fangfang Lai, et al.
Published: (2022)